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Because of the difficulty and expense of objectively 
measuring psoriasis severity, very little information 
exists on the severity of psoriasis in populations. We 
d etermined severity in a psoriasis patient population 
using the validated self-administered psoriasis area 
and severity index (SAPASI). This population con-
sisted of 578 university dermatology clinic psoriasis 
patients, and data were analyzed from 317 (55°/.,) 
questionnaire respondents. The majority of our sam-
ple was women (57%), and non-Caucasians repre-
sented a larger portion (8'Yo) in our sample compared 
with some previous studies . In our population, the 
P soriasis a(fects up to 2'X, of the population (Elder e/ nl, 1993) . Altho ugh stud ies have documen ted characte ris-tics of psoriasis populations (Lumbolt, 1963; H ell gren , . 1967; Farbe,' and Na il , 1974; National Center fo r Health Statistics, 1979; C urrent Estimates, 1993; Elder 
e/ nl, 1993) , there has been littl e efFort to systematica lly characterize 
the severity of psoriasis in these populations. In dinical trials, the 
severi ty of psoriasis has traditionall y been assessed by measures such 
as the psoriasis area and severi ty index (PASl) (Fredricksson and 
Peterson, 1978), psoriasis severi ty scores (Perkins e/ nl, 1993), and 
les ional severity scores (Townsend ef nl, 1995). Although these 
m easurem ent techniques may be helpful in evaluatin g a few 
subjects, they require administratio n by trained person nel and they 
are time consuming. 
We have previo usly develo ped and validated a self-administered 
psoriasis area and severity index (SAPASI) instrument, w ith w hich 
patients assess their own disease severity (Feldm an e/ nl, 1994; 
Fleischer e/ nl, 1994b) . In thi s study we re port the severity of 
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reported frequencies of skin andjoint symptoms were 
as follows: pruritus (95%), skin burning (81%), joint 
pain (69%), arthritis (51%), and psoriatic arthritis 
(20'10). The SAPASI was significantly associated with 
severity of pruritus, burning, joint pain, and psoriatic 
arthritis. There was a significant negative correlation 
between the number of treatments employed and the 
SAP AS!. This study provides results of a detailed 
measurement of the severity of psoriasis in a psoriasis 
patient population and relates this severity to popu-
lation characteristics. Key Ivol'ds: epidemiology/al'tllI'itisl 
pl'IlI'itlls/skill disease. ] J,,,,est Del'ma.to l 107:26-29, 1996 
psoriasis in a local population using th is instrument. Furthermo re, 
to assess the degree to which o ur sample is representa tive of other 
psoriasis samples, we compare dem ographics and disease attribu tes 
of our p opulation o f p soriasis p atients with other American p opu-
latio n studies . 
M ETHODS 
Subjects in thi s study were patients presenting to the Wake Forest 
University Department of Dermatology w ho had rece ived a clin ica l diag-
nosis or psoriasis vulga ri s betweelJ Ma y, 1992, and December, 1993. 
Subjects were 18 y and older , iden tified £i'om electronic billing records of all 
dermato logy patients diagnosed w ith psoriasis. Because o ur stud y was 
designed with extensive quali ty of li fe instrumentation, we excluded 
children fro m o ur stud y. l'l...esults fro m the quality of li fe studies w ill be 
presented e lsewhere. A survey eliciting informatio n o n demographics, 
therapeutics, m edical expenses, co-existing m edical conditio ns, psychoso-
cial fUll ction ing, and quali ty of life was mailed to participants between April 
and October of 1994. Focus gro up sessions we re conducted w ith psoriasis 
patients to determine w hich symptom s sho uld be included in the survey 
instrument . Subjects were specifica ll y asked abo ut j o int problem s and 
whether they had been diagnosed w ith arthdtis of different types, but no 
attempt was m ade to substantiate arthritis diagnostic claims. Treatments 
employed by responden ts were defined as any agent o r preparation used to 
treat psoriasis, including such over-the- counter agents as em ollien ts and 
coal tar. 
The severity o f psoriasis was assessed in thi s survey with the SA llAS!. T llis 
instrumen t consists of a silho uette of a body, front and back, for subjects to 
shade in affected areas and of three modifi ed visual analog scales (V ASs) for 
recording the redness, thi ckness. and sca ljness of all average les ion . O n each 
120-mm V AS, extrem es and in termediate leve ls were labe led . For instance, 
the VAS for e rythema conta ins the fo llowing word descriptions: 110 redness, 
sligh t pink, pink, red , dark rcd. A random sample of30 SAPASI fo rms were 
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scored by a second investigator (SKF) , and comparison with the primary 
rater showed the inter-rate r "e liabi lity of the SAPAS I to be 97'X, and 
body-site-specific. in ter-rater re liabili ty to be between 96 and 100'y.,. 
To increase the respo nse rate to the survey, we sent cover letters 
explaining the nature of th e SlIT-VCY; fo llow up phone calls "vere Illud e and 
add itional surveys were mailed if necessa ry. A total of 578 anonymous 
surveys were distributed of w hich 318 were returned for a response rate of 
55% . 
To dete rmine if the survey responders d iffered from nonresponders. we 
perfornled a c hart revi c \o\r of 25 randolfd y c hosen responders and 25 
random ly chosen nonresponders . O ne responder chart could not be located. 
C h art reviewers were unaware of the response status. Information collected 
included race . gender. age. number of dermatologic visits in '1994 . severi ty, 
presence o r absence of psori asis, and treatments. To compare treatment 
modalities in thi s chart review as we ll as the survey responses. a treatment 
intensity was assigned accord ing to the fo llowing ranking system: 1 = over 
the CO llllter emolJients, ta r, suns hille; 2 = prescriptioll topica l agen ts, ora l 
antibiotjcs, and oth e r ll1inor trcatnl e n t; 3 = physic ian-adnlini stc red photo-
therapy and sys temic agents including etre tinate and methotrexate. Severity 
of psoriasis was assessed taking into account the recorded body surface area, 
severity aSSCSS ITI Cll tS. and clini cal desc riptio ns by a single c h a rt rcvic \,vcr. 
These ratings were I = mild , 2 = moderate, or 3 = severe. 
T he SAPAS I is a con tinuous measure of psoriasis severity. W hen 
ca tegorization was required for analysis, we defined the psorias is as in 
remission w hen SAPAS I = 0, mild whell 0 < SAPAS l ::; 3, moderate w hen 
3 < SAPAS I ::; "1 5, and severe when SAPAS I > 15. T hese categorizations 
were derived n prior; by the consensus of two of the authors (ABF and SRF) 
based upon consideration of the body sur[;lce area, severity ratings. and their 
respective clinical appearances. All data processing was performed with the 
SAS system (SAS Ins titute, Cary , NC). 
Because we were not able to se lect a random sample of the loca l psoriasis 
population, we compared our patiellts in the survey with the five other 
studies c ited below with respect to several va riables common to all sources : 
age, sex, a nd race . 
Fnrber nlld Nn ll (1974): a nonrandom sample of 5600 psoriasis patients 
recruited from dermatology offices. 
Koo (1995) : a survey of psoriasis pa tients based upon a random sample of 
5000 households. ' 
N nl;ollnl H enllh /lIl e/"ll;e,I' SII/"IIe)' (NH IS 1993): a random sample of 
individua ls that includes information on psoriasis. 
N nl;Ollnl A",b ,linlol"}' Med;ca l Cnre S II /"IIe)' (NAMCS): a random sample of 
physicians that includes information on psoriasis oR-icc visits (U.S. Dept of 
Health and Human Services, 1992). 
Henlll, nlld N lllr;lic", Exn"';lI nl;oll S",."e)' (HANES): A random sample of 
the civilian noninstitu tiona li zed population Uohnson and H..oberts, '1978; 
National Center for Health Statistics, 1979). 
Although obtai lied using nOll validated technjques, proxy measures of 
severity we re ava ilab le in the HANES study and that of 1(00, and 
information on body sites was ava ilab le in Koo's study. For the NJ-IIS study, 
we had infornla tiol1 o nl y on p reva le nce of psoriasis "vithill age. sex , and ra ce 
categories. T hese rates were combined w ith corresponding data fro m the 
U .S. Census Bure;\U (1994) to produce a profi le of psoriasis patients 
included. 
RESULTS 
Deltlographic Variables T h e mean age of responde nts was 
48.8 ::!:: 14.6 (mean ::!:: SD), w ith a range of 18 to 91 y. T h e racia l 
composition was predominantly Cau casian (91 % ), although several 
oth er racial groups were represented including Afi'ican A m erican 
(6%), Native Americ an (1%,), and less than 1% each of Asian 
American, Hispanic, and other races. T h e re w e re more women in 
our sample (180; 57% ) than m en (135; 43%). 
Our population had received the diagnos is of psoriasis 14.4 ::!:: 
12.8 y (mean ::!:: SD) prior to comple ting the survey. T h e mean age 
of psorias is onset of 34.5 ::!:: 17.1 y. Freq u e ncies of co-existin g 
conditio n s are presented in Table I. 
Severity The severi ty of psoriasis in o ur population h ad th e 
fo ll owing distribution: remission, 7 (2%); mild, 124 (39% ); m o d-
erate, 158 (50%); and severe, 29 (9'1.,). T h ese severity ratings 
correspond with mean ( ::!::SD) SAPASI score of7.7 ::!:: 7.8. Thirty-
eight (11.9%) of respondents h ad been hospitalized for psoriasis at 
, Koo J: T he American Psoriasis R.eport, unpubli shed data presenred w ith 
permission of author and Westwood-Squibb Pharmace uticals, Inc. 
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Table I. Co-Existing Conditions 
Condition Frequency (n = 318) 
Hypertension 
Gastro in testi nal diseases 
Heart di sease 
Thyro id di sease 
Urinary tract disease 
M elltal h ea lth conditions 
Neuro logic disease 
Lung disease 
lnlnlullolog ic disease 
Cancer 
Liver d isease 
81 (25.5%) 
53 (16.7%) 
35 (11 %) 
30 (9.4%) 
26 (8.2%) 
18 (5.7%) 
16 (5%) 
13 (4.1%) 
9 (2.8%) 
9 (2.9%) 
8 (2 .5%) 
some time in the past. Figure 1 sh ows th e anatomic distribution of 
p sori as is in o ur population at th e ti m e of th e survey compared with 
th at of Koo's popu.lation . 
Most of our population experienced discomfort from psoriasis 
(Fig 2). In o ur population, th e frequencies of skin symptoms were 
as follows: 95% reported pruritus, 81 % reported skin burning, and 
86% reported sore skin. F igure 2 shows the distrIbution of the 
severity of each of th ese skin symptoms. A regression of the 
SAPASI o n disease-relate d symptom s found th at th e SAPASJ 
pre dicted the severity of pruritus (p = 0.004), burning (p = 0 .04), 
and skin soreness (p = 0.0001). 
Arthralgias and Arthritis When asked if th ey h ad joint pain, 
219 (69% ) stated tha t they h ad a li t tl e or more (Fig 2) . Over h al f of 
respondents (163; 51 %) stated they had arth ritis , and 64 (20% ) 
stated th ey had psoriatic arthritis. Oth e r self-repo r ted types of 
arthritis in responde nts included rhe umatoid arthritis (23; 7%) and 
osteoarthritis (19 ; 6"1<,). There were modest but significant correla-
tion s between th e SAPASI <lndjoint pain (r = 0.3, p = 0.0001) and 
psoriati c arthritis (r = 0 .3, P = 0.0003). 
Psoriasis Treatlnent The mean daily number of minutes of 
psoriasis ca re was 68.2 ::!:: 90.0 (mean ::!:: SD), and the range was 0 
to 600 min. The extremely high care times reported by a small 
numbe r of respondents were due to the ir current treatment in an 
o utpatient psoriasis day care center. One hW1dred sixty-four re-
spondents (51 % ) spent more than 60 min per d ay caring for their 
psoriasis. There was a modest but significant correlation of the 
SAPAS I and the time spen t caring for psoriasis (r = 0.32 , p = 
0.0001 ) . 
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Figure 1. The body sites affected in our psoriasis population 
compared with Koo's reference psoriasis population. WFUPS is the 
Wake Forest University Psoriasis Study and asterisks (0) represent unavail-
able data. 
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Figure 2. Proportion of the WFUPS population with complaints of 
pruritus, skin burning, sore skin, and joint pain . 
T he numbe r of over-th e- counter and prescrip tion treatm ents 
being used by respondents ranged fro m 5 to 15 and had a m ean of 
12. 1 :!:: 1.8. T here was a modest but significant negati ve correlatio n 
between the number of treatments and the SAPASI (r = - 0.2, P = 
0.0001 ) . 
T he in tens ity of treatment was highl y variable and is depicted in 
F ig 3 . Overall , 23% utilized intense treatment, 61'X. utilized 
moderate treatment, and 16% utilized over-the-coun te r treatm ent. 
There was no signifi cant re lati onship between the intensity of 
treatment and the SAPASI (r = - 0.1, P = 0.09) . O f note, two of 
the seven (29%) responden ts in remissio n were currently usin g 
in tens ive therapy. T here was a sma ll but signifi ca nt negative 
correlation between the in tensity and the psoriasis ca re time (r 
- 0.14,. p = 0.01). 
Differences in Demographic Variables In o ur sampl e , m en 
and women did not differ in age, severity of itching, severi ty of 
burning, current number of psoriasis trea tn1ents, in tensity of treat-
m ent, or tim e spen t caring for psoriasis (p > 0. 1) . Men had more 
severe psoriasis (SAPASI m ean 8 .3) than wom en (SAPASI m ean 
7.2) (p < 0.0001) . Also, in comparing Caucasian and no n-Ca uca-
sian respondents, we found no racia l differences in age (p = 0.5) , 
itching (p = 0.6), burn ing (p = 0 .5) , joint pai n (p = 0.8), curren t 
number of psori asis treatments (p = 0.6) , in tens ity of treatment (p 
m 
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F ig ure 3. T he intensity of treatment by the psorIasIs disease 
severity ;11 the WFUPS population. Sec Me/hods for description of 
in tensity and severity measures. 
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F igure 4. The psoriasis disease severity of the WFUPS population 
as measured by the SAPASI compared with nonvalidated measures 
in Koo and HANES. 
= 0.3), or time spen t caring for psonasls (p = 0.8). N o n-
Ca ucasians, however, had m ore severe psoriasis (SAPAS I m ean 
9 .8) than Ca ucasians (SAPAS I mean 7.5) (p < 0.0001). 
Comparisons with Other Studies T he age, sex, and race 
distributions of o ur sample were not markedl y diffe rent from those 
in other studies. Our sa mpl e conta in ed a hi gher propo rtion of 3U-
to 49-yr-old respondents than those of NHI S, NAMCS, or Farber 
and Nail. T he proportio n of women was higher than in NAM CS 
but lower than in groups studied by Farber and Nail, Koo , NHIS , 
or HANES. The overwh e lmin g majority of pso rias is pat ients in .111 
stud ies , includin g o urs, are Ca ucas ian, and the pro portio n in o ur 
study was similar to that in studies of Koo and HANES. W e 
o bserved more patients w ith moderate to severe psoriasis than ill 
the HAN ES and Koo studi es (Fig 4) . 
Responders and Nonresponders Were Similar T he chart 
review confi rm ed that our respo nders were representative of our 
po pulation (Table II) . T here was no statistical difference between 
responders and no nresponders in regard to sex (p = 0.5), race (p = 
1.0) , or age (p = 0.4). T he re were no signifIcant diffe ren ces in 
dermatology service utiliza tion in 1994, treatm ent intensity, or 
psorias is disease severity (p = 0.9,0.4 , and 0 .1 , respectively). 
T he re was a differe nce in the numbe r of respo nders w ho did no t 
have psoriasis. In fact, 32% of nonresponders (8 of25) did not have 
psoriasis compared with 0% of respo nd ers (p = 0.002). N on-
psoriatic diagnoses included small plaque parapsoriasis, cu taneous 
Table II. Survey Responders and Nonresponders Have 
Similar Demographics and Severity 
Respollders N on-responders 
With With p 
Pso riasis" Psoria sis'" Value 
Dermato logy visits in 1994 2.0 (3 .8) 1.4 (2.2) 0.9 
Age 52 (13) 45 (,15.7) 0 .4 
Trcatnl c n t intensity 2 .0 (0 .9) 1.8 (0.8) 0 .4 
Severi ty 1.6 (0. 8) 2 (0.9) 0.1 
Sex 
Male '10 9 0.5 
Female 14 8 
Race 
C aucas ian 22 15 
Ulack 2 2 1.0 
Asian () 0 
" Mcan (st:lIlc{;,rd de viation). 
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T - cell lympho ma, lichen simplex chrollicus, and psoriasiform der-
mati t is. Incorrect diagnostic coding b y the in stitution may have 
accounted fo r the presence of non-psoriatic patie nts in this data-
base. 
DISCUSSIO N 
T he Wake Forest Uni versity Pso riasis Study provides important 
in sig h ts in to the epide miology of pso riasis usin g a va lidated instru-
m ent. T he SA PASI allows fo r compariso n of disease severi ty with 
other characteristics in a new and efficient manner. T his study also 
presen ts the characteris tics of our sample in re lationship to severity. 
Q ualj ty of li fe and psychosocial iJlstruments were admin istered at 
the sa m e time as th e above disease characteristic m easures and wil l 
be the subject of future reports. 
M e n and no n-Caucasians had m o re severe psoriasis. T hese 
groups m ay develop m o re severe psorias is on th e ba sis in trinsic 
sex ual and rac ial ditre rences. Alte rn ative exp lanations may exist as 
well. For the racial difFe rence, we have already d emonstrated that 
min o ri tes have less access to derm ato logic health care (Fl eischer el 
ai, 1994a). W e hypothesize that this underutili za tion of phys ician 
serv ices by minOl'ity patients ma y acco unt for a large measure of the 
increased disease severity. 
Pruritus in psoriasis has previo usly been studi ed in the inpatient 
populatio n . G upta el al (1 988) reported tha t 67% had moderate to 
severe pruritus. Altho ug h we cannot directl y compare our OlItpa-
tient data beca use of difFeren t m etho do logic approaches, 76% of o ur 
population reported pruri tus that bo thered them moderately or a lot. 
Both studies concUl' that itclung is very common and bothersome. 
A rthri tis was also a common conditio n in tl'tis group. Our 20'Yu 
prevalence of pso ria tic arthritis mirrors the prevalence figures cited 
b y Stern (1 985), O riente el al (1 989), and Zano Hi and W in k le 
(1992) . A limitati o n of the cu rrent study is that o ur survey 
in strum en t did not recOl'd hi stori cal a ttributes of the arthritis 
diagnostic process, and thus o ur nrthritis fi g ures are subject to 
question. Despite these limitations, future analys is of these data will 
be required to assess th e contribution of joint complaints and 
disease to psoriasis-related di sability and hea lth-re lated quali ty of 
jjfe . Our o bserved high preva lence of arthralgias confirms the 
previo us find ing that thi s po pulation h ;]s a high rate of mino r 
muscul oskele tal symptoms. 
O ur popul ;]tio n demon stra ted that psoria sis may have a profo und 
impact on the da il y li ves of patients. H alf of th is population spent at 
least an ho ur each day caring for their skjn . Mo reove r, the 
prevalence of burning, pruritus, and j o int pain suggests that these 
patients ex perience signi ficant disease-re lated morbidity. 
T he intensity of treatm ent in this population is challenging to 
qua·ntita te. N everthe less, the separatio n of therapeu tic modalities 
into groupings including over-the-coun ter, moderate intensity, and 
intensive treatment provide a tool for understanding o ur popula-
tion. It is noteworthy that som e pati ents utili zing the m ost intensive 
therapy had li ttle psorias is disease severity, suggesting that such 
treatments work. Our lack of corre lation between treatment inten~ 
sity and psoriasis severi ty underscores the heterogeneity of the 
population . 
T he re are similarities and diffe rences in d emographi c attributes 
compared with other psoriasis epidemio logic studies . Al l of the 
studi es to da te, including our study , have biases that influence the 
d emographic attributes of the participants. O ur population con-
tained 8'X, non-Ca ucasians, compa rabl e w ith the populati on-based 
study repo rted by Koo . T he hig he r propo rtion of middle- aged 
subj ects we observed may be due to olir excl usion of cluJdren. 
T he psoriasis disease severi ty th at we m easured in o ur population 
is greater than that o bserved by Koo using a verbal, subjective 
survey technique, o r by the HAN ES using a no n validated physici;]n 
technique. For instan ce, o nl y 2% of o ur popul ;]tion was in remiss io n 
compared w ith 24% in the Koo study and 15% in the HANES. An 
additi o nal o bstacle .in making compariso ns ari ses fi'om o ur m e tho d 
of distribution to known psorias is patients diagnosed by dennatol-
ogists. In the HA N ES, if no disease was visible, w e could question 
the re \j;]bility of the di;] gnosis of pso ri as is in remissio n . Similarly, 
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the Koo study rel.i es entirely upon self reporting, and psorinsis may 
be con fused w ith atopic dermatitis, li chen simplex chronicus, and 
other diseases. Despite the above d iffi cul ties, we cannot exclude the 
possibili ty that o ur po pulatio n had a m ore severe distribution of 
psorias is severity than the gener;]] population. 
Altho ugh not the m ain focus of this study. these data provide 
evidence bolstering the va li dity of the SAPAS I. O ur previous 
in strument va lidation studi es have demonstrated crite l;on vaUd ity, 
re liabili ty, and responsiveness (Fe ldman el al. 1994; Fleischet· ('I ai, 
1994b) . In contrast to criterio n va lidity, which compa res a m easure 
w ith the "gold standard ," constru ct va lidity assesses w hether a 
m easure actual.l y m easures what it is purported to measure. We 
fo und signjficant rela tio nships between the SAPASI and the fol-
lowing variables : tim e spent ca rin g for pSOl;asis, number of treat-
m en ts, pruritus, skjn burning, skill soreness, arthritis, psoriatic 
;]rthritis. and j oint pain . Because each of the above cited relatio n-
ships between SAPAS I an d psoriasis is intimately related with 
psoriasis morbidi ty , this study suppo rts the construct va lidi ty of th e 
SAPASl. 
Alth o ugh the severity o f pso ri as is is clearl y impo rtant, there arc 
o ther important aspects of psoriasis care that are either directl y o r 
indirectly related to patient ca re that mu st be considered, including 
di sabili ty and social stigma tization . 
T "is p"bli(al ilJ/1 ,/'as II mdl' possible by gra llllllllllber MH 5 1552 10 Slep"clI R. Rapp 
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